Threshold Pharmaceuticals, Inc (THLD): Opiniones

Tanto por técnico como por fundamentales.

Muchas gracias a todo el que se anime a contestar.

Ratios financieros:

Noticias:
18 Nov 2010 08:25am EST

Threshold Pharmaceuticals, Inc. announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. Today's presentation focused on two clinical trials, the 402 trial and the 403 trial. The 402 trial is a Phase 1/2, three arm, multicenter, dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine (Gem) or docetaxel (Doc) or pemetrexed (Pem) in patients with various advanced solid tumors including, but not limited to, advanced or metastatic pancreatic cancer, castrate-resistant prostate cancer (CRPC) and relapsed or refractory non-small cell lung cancer (NSCLC). The 403 trial is investigating TH-302 in combination with doxorubicin (Dox) in patients with advanced soft tissue sarcoma. Additionally, in the gemcitabine treatment arm, median progression free survival (PFS) was 6.4 months (95% CI: 4.7 to 7.7 months). Among the patients with relapsed or refractory NSCLC, median PFS was 4.2 months (95% CI: 2.8 months to not reached). Among the 15 patients with CRPC, 11 (73%) had a PSA decline of at least 50%. Among the patients with soft tissue sarcoma, median PFS was 6.4 months (95% CI: 5.6 to 6.9 months). Overall, hematologic toxicity was acceptable and skin and mucosal toxicities were well managed at current dose levels.

Fuente: Reuters

Gracias Enrique por la info facilitada.

Esta compañía no encajaría con Zeltia?
No sé , la voy a seguir...por si las moscas.

Si pasa 1.61 fiesta:)

Volumen bonito,

Figura de vuelta a por los 2$

Atentos que va fuerte. Esto pinta muy bien